Co-Authors
This is a "connection" page, showing publications co-authored by AHMED KASEB and MICHAEL CURRAN.
Connection Strength
0.761
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
Score: 0.250
-
Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma. Oncology. 2024 Oct 18; 1-20.
Score: 0.249
-
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1195-1207.
Score: 0.201
-
Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial. Clin Mol Hepatol. 2024 Jul 23.
Score: 0.061